Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intravenous immunoglobulin (IVIG) vs corticosteroids Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs corticosteroids Time to complete re‐epithelialisation ‐ not reported · treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs corticosteroids Intensive care unit (ICU) length of stay ‐ not reported · treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs corticosteroids Total hospital length of stay ‐ not reported · treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs no corticosteroids Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs corticosteroids Adverse effects leading to discontinuation of SJS/TEN therapy ‐ not reported (see comments) · treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs corticosteroids Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs corticosteroids Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs corticosteroids Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs corticosteroids Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs corticosteroids Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs intravenous immunoglobulin (IVIG) Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs intravenous immunoglobulin (IVIG) Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs intravenous immunoglobulin (IVIG) Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs intravenous immunoglobulin (IVIG) Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs no corticosteroids Total hospital length of stay – not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs intravenous immunoglobulin (IVIG) Adverse effects leading to discontinuation of SJS/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs intravenous immunoglobulin (IVIG) Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs intravenous immunoglobulin (IVIG) Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs intravenous immunoglobulin (IVIG) Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Cyclosporin vs intravenous immunoglobulin (IVIG) Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs cyclosporin Disease‐specific mortality ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs cyclosporin Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs cyclosporin Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs cyclosporin Total hospital length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Corticosteroids vs no corticosteroids Adverse effects leading to discontinuation of SJS/TEN therapy – not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Etanercept vs cyclosporin Adverse effects leading to discontinuation of SJS/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin (IVIG) vs no IVIG Intensive care unit (ICU) length of stay ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN),… (2022) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only ADHD symptoms · people with ADHD and epilepsy Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Osmotic‐release oral system methylphenidate vs placebo Proportion of people experiencing 50% or greater reduction in seizure frequency · people with ADHD and epilepsy Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only Seizure severity · people with ADHD and epilepsy Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy (2022) · Cochrane | no estimate extracted | NR | No studies |
Ocrelizumab vs placebo Number of participants with gadolinium‐enhancing T1 lesions on MRI · people with primary progressive multiple sclerosis Ocrelizumab for multiple sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Ocrelizumab vs placebo Number of participants with new or enlarging T2‐hyperintense lesions on MRI · people with primary progressive multiple sclerosis Ocrelizumab for multiple sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
14 days on/off antibiotic regimen vs 28 days on/off antibiotic regimen Exacerbation frequency · people with bronchiectasis Intermittent prophylactic antibiotics for bronchiectasis (2022) · Cochrane | no estimate extracted | NR | No studies |
14 days on/off antibiotic regimen vs 28 days on/off antibiotic regimen Frequency of hospital admissions for pulmonary exacerbations ‐ not measured · people with bronchiectasis Intermittent prophylactic antibiotics for bronchiectasis (2022) · Cochrane | no estimate extracted | NR | No studies |
14 days on/off antibiotic regimen vs 14 days on/off placebo regimen Frequency of hospital admissions for pulmonary exacerbations ‐ not measured · people with bronchiectasis Intermittent prophylactic antibiotics for bronchiectasis (2022) · Cochrane | no estimate extracted | NR | No studies |
ISBCS vs DSBCS Total costs per QALY · people with bilateral age‐related cataracts (NRSs) Immediate sequential bilateral surgery versus delayed sequential bilateral surgery for cataracts (2022) · Cochrane | no estimate extracted | NR | No studies |
ISBCS vs DSBCS BCDVA · people with bilateral age‐related cataracts (NRSs) Immediate sequential bilateral surgery versus delayed sequential bilateral surgery for cataracts (2022) · Cochrane | no estimate extracted | NR | No studies |
ISBCS vs DSBCS PROM · people with bilateral age‐related cataracts (NRSs) Immediate sequential bilateral surgery versus delayed sequential bilateral surgery for cataracts (2022) · Cochrane | no estimate extracted | NR | No studies |
ISBCS vs DSBCS Total costs per QALY · people with bilateral age‐related cataracts (RCTs) Immediate sequential bilateral surgery versus delayed sequential bilateral surgery for cataracts (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise plus PD&P vs PD&P only Quality of Life: change in CFQ‐R score · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise plus PD&P vs PD&P only Participant preference · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise plus PD&P vs PD&P only Need for extra antibiotics (days) · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Pulmonary function: absolute change FEV1 % predicted · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Change in VO2 peak during maximal exercise · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Quality of life: change in CFQ‐R score · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs ACBT Change in VO2 peak during maximal exercise · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Adherence · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Need for extra antibiotics (days) · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs ACBT Quality of life · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |